Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBMG's Cash-to-Debt is ranked higher than
86% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CBMG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBMG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
CBMG's Equity-to-Asset is ranked higher than
96% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBMG: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
CBMG' s Equity-to-Asset Range Over the Past 10 Years
Min: -279.5  Med: 0.88 Max: 0.97
Current: 0.93
-279.5
0.97
Interest Coverage No Debt
CBMG's Interest Coverage is ranked higher than
83% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBMG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CBMG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 16.47
Beneish M-Score: -5.63
WACC vs ROIC
20.62%
-102.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -12976.86
CBMG's Operating Margin % is ranked lower than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CBMG: -12976.86 )
Ranked among companies with meaningful Operating Margin % only.
CBMG' s Operating Margin % Range Over the Past 10 Years
Min: -24440  Med: -2391.7 Max: -126.02
Current: -12976.86
-24440
-126.02
Net Margin % -12736.68
CBMG's Net Margin % is ranked lower than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CBMG: -12736.68 )
Ranked among companies with meaningful Net Margin % only.
CBMG' s Net Margin % Range Over the Past 10 Years
Min: -24660  Med: -2347.1 Max: -122.17
Current: -12736.68
-24660
-122.17
ROE % -43.11
CBMG's ROE % is ranked lower than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CBMG: -43.11 )
Ranked among companies with meaningful ROE % only.
CBMG' s ROE % Range Over the Past 10 Years
Min: -245.45  Med: -56.74 Max: -43.11
Current: -43.11
-245.45
-43.11
ROA % -41.39
CBMG's ROA % is ranked lower than
60% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CBMG: -41.39 )
Ranked among companies with meaningful ROA % only.
CBMG' s ROA % Range Over the Past 10 Years
Min: -617.21  Med: -84.85 Max: -41.39
Current: -41.39
-617.21
-41.39
ROC (Joel Greenblatt) % -677.45
CBMG's ROC (Joel Greenblatt) % is ranked lower than
59% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CBMG: -677.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBMG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1084.27  Med: -1029.83 Max: -677.45
Current: -677.45
-1084.27
-677.45
3-Year Revenue Growth Rate 9.50
CBMG's 3-Year Revenue Growth Rate is ranked higher than
60% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CBMG: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBMG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.65 Max: 81.7
Current: 9.5
0
81.7
3-Year EBITDA Growth Rate 1.70
CBMG's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CBMG: 1.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBMG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -10.7 Max: 76
Current: 1.7
0
76
3-Year EPS without NRI Growth Rate 2.20
CBMG's 3-Year EPS without NRI Growth Rate is ranked higher than
54% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CBMG: 2.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBMG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 379.5
Current: 2.2
0
379.5
GuruFocus has detected 7 Warning Signs with Cellular Biomedicine Group Inc $CBMG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBMG's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CBMG Guru Trades in

CBMG Guru Trades in

CBMG Guru Trades in

Q2 2015

CBMG Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBMG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:NAS:VCEL, NAS:TRVN, NAS:GNCA, NAS:ADVM, NAS:XOMA, NAS:REPH, NAS:PPHM, OTCPK:HPPI, NAS:BDSI, NAS:XBIT, TSX:VBV, NAS:SRNE, AMEX:AST, NAS:CEMP, NAS:RGLS, NAS:ALPN, NAS:ALDX, NYSE:KDMN, NAS:ALRN, NAS:GTXI » details
Traded in other countries:1LX.Germany,
Headquarter Location:USA
Cellular Biomedicine Group Inc is a part of the healthcare sector. It is engaged in the development of new treatments for cancerous and degenerative diseases.

Cellular Biomedicine Group is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.

Top Ranked Articles about Cellular Biomedicine Group Inc

Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin™
Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference
Cellular Biomedicine Group (CBMG) Announces Stock Repurchase Program
Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)
Cellular Biomedicine Group Announces Results of 2017 Annual Meeting of Stockholders
Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies
Cellular Biomedicine Group (CBMG) Announces Completion of Wuxi GMP Facility Expansion

SHANGHAI, China and CUPERTINO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a leading clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the completion of its newly expanded 30,000 square foot facility in Huishan High Tech Park in Wuxi, China. 20,000 square feet of the Wuxi GMP facility will be dedicated to advanced stem cell culturing, centralized plasmid and viral vector production, cell banking and development of reagents.  By the end of 2017, the Company anticipates that the combination of this Wuxi site, the new Zhangjiang Shanghai and the Beijing GMP facilities will be capable of supporting simultaneous clinical trials for five different CAR-T and stem cell products, or capacity to treat up to 10,000 cancer and 10,000 Knee Osteoarthritis (KOA) patients per year.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5e253f76-4330-47de-bae1-a47fd6aaff31 “As we have previously stated, this marks a key milestone in our corporate development in the first quarter of 2017 as we continue to invest in and expand our capabilities in advanced CAR-T and stem cell manufacturing.  We have long recognized the logistical challenges of delivering consistent, quality and clinical grade processes to deliver cell therapies to market and we have differentiated our capabilities to meet this challenge. We will now be able to centralize, standardize and automate our manufacturing capabilities fully in-house while enhancing our capacity to meet the production demands of multiple products in development as part of our overall Chemistry, Manufacturing, and Controls (“CMC”) process,” said Tony (Bizuo) Liu, Chief Executive Officer of Cellular Biomedicine Group. “The Wuxi facility is equipped with six independent production lines and will be capable of producing and banking low endotoxin high transfection rate plasmids, and high titer automated and purified virus with stringent quality control,” commented Helen Zhang, SVP of Technology & Manufacturing for CBMG. CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19 B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19 B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. To learn more about CBMG, please visit www.cellbiomedgroup.com. Forward-looking Statements
This press release contains forward-looking statements—including descriptions of plans, strategies, trends, specific activities, investments and other non-historical facts—as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently uncertain, and actual results could differ materially from those anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy (including the devaluation of the RMB by China in August 2015), and other risks detailed in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," "continue" or similar terms or their negations. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law. The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
1 408-973-7884
[email protected]

Vivian Chen
Managing Director Investor Relations, Citigate Dewe Rogerson
1 347 481-3711
[email protected] 

Read more...
Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders

SHANGHAI, China and CUPERTINO, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 28, 2017. The meeting will be held at the Company’s office at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California 95014 at 9:00 a.m. PDT. Stockholders of record as of March 10, 2017, the record date for the meeting, are authorized and asked to vote in the manner directed in the proxy materials.
A stockholder, once having received his/her proxy notice and access card, may view the proxy statement and related materials online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59 p.m., Thursday, April 27, 2017, EDT. If your shares are held in the name of a bank, broker or other nominee, please check with your bank, broker or nominee and follow the voting instructions it provides. Please send an email to [email protected] if you have questions about the Annual Meeting or have not received your proxy notice card by post or by email. About Cellular Biomedicine Group (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
1 408-973-7884
[email protected]

Vivian Chen
Managing Director Investor Relations, Citigate Dewe Rogerson
1 347 481-3711
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.74
CBMG's PB Ratio is ranked higher than
75% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CBMG: 2.74 )
Ranked among companies with meaningful PB Ratio only.
CBMG' s PB Ratio Range Over the Past 10 Years
Min: 0.48  Med: 2.89 Max: 360
Current: 2.74
0.48
360
PS Ratio 662.52
CBMG's PS Ratio is ranked lower than
95% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CBMG: 662.52 )
Ranked among companies with meaningful PS Ratio only.
CBMG' s PS Ratio Range Over the Past 10 Years
Min: 2.22  Med: 98.04 Max: 1222.22
Current: 662.52
2.22
1222.22
EV-to-EBIT -4.12
CBMG's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CBMG: -4.12 )
Ranked among companies with meaningful EV-to-EBIT only.
CBMG' s EV-to-EBIT Range Over the Past 10 Years
Min: -867.8  Med: -6.9 Max: 100.2
Current: -4.12
-867.8
100.2
EV-to-EBITDA -4.52
CBMG's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CBMG: -4.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBMG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -867.8  Med: -7.3 Max: 100.2
Current: -4.52
-867.8
100.2
EV-to-Revenue 533.85
CBMG's EV-to-Revenue is ranked lower than
91% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CBMG: 533.85 )
Ranked among companies with meaningful EV-to-Revenue only.
CBMG' s EV-to-Revenue Range Over the Past 10 Years
Min: -281.8  Med: 117.4 Max: 1229.6
Current: 533.85
-281.8
1229.6
Current Ratio 6.50
CBMG's Current Ratio is ranked higher than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CBMG: 6.50 )
Ranked among companies with meaningful Current Ratio only.
CBMG' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.76 Max: 23.51
Current: 6.5
0.01
23.51
Quick Ratio 6.50
CBMG's Quick Ratio is ranked higher than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CBMG: 6.50 )
Ranked among companies with meaningful Quick Ratio only.
CBMG' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.52 Max: 23.38
Current: 6.5
0.01
23.38
Days Inventory 705.22
CBMG's Days Inventory is ranked lower than
83% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CBMG: 705.22 )
Ranked among companies with meaningful Days Inventory only.
CBMG' s Days Inventory Range Over the Past 10 Years
Min: 34.81  Med: 82.97 Max: 705.22
Current: 705.22
34.81
705.22
Days Sales Outstanding 145.04
CBMG's Days Sales Outstanding is ranked lower than
79% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CBMG: 145.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBMG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.59  Med: 59.61 Max: 243.61
Current: 145.04
19.59
243.61
Days Payable 3.00
CBMG's Days Payable is ranked higher than
98% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CBMG: 3.00 )
Ranked among companies with meaningful Days Payable only.
CBMG' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 91.67 Max: 644.03
Current: 3
3
644.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.60
CBMG's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CBMG: -24.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBMG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -95.4  Med: -11.55 Max: -3.8
Current: -24.6
-95.4
-3.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.58
CBMG's Price-to-Net-Cash is ranked higher than
73% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CBMG: 6.58 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CBMG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.73  Med: 12.17 Max: 42.84
Current: 6.58
1.73
42.84
Price-to-Net-Current-Asset-Value 6.02
CBMG's Price-to-Net-Current-Asset-Value is ranked higher than
72% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CBMG: 6.02 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBMG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.63  Med: 11.23 Max: 320.5
Current: 6.02
1.63
320.5
Price-to-Tangible-Book 4.36
CBMG's Price-to-Tangible-Book is ranked higher than
67% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CBMG: 4.36 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBMG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17  Med: 5.09 Max: 300
Current: 4.36
1.17
300
Price-to-Median-PS-Value 6.75
CBMG's Price-to-Median-PS-Value is ranked lower than
95% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CBMG: 6.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBMG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.99 Max: 7.06
Current: 6.75
0.05
7.06
Earnings Yield (Greenblatt) % -24.31
CBMG's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CBMG: -24.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBMG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -80  Med: -11.8 Max: 3.6
Current: -24.31
-80
3.6

More Statistics

Revenue (TTM) (Mil) $0.23
EPS (TTM) $ -2.03
Beta3.07
Short Percentage of Float1.91%
52-Week Range $5.05 - 15.45
Shares Outstanding (Mil)14.11

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 0 25
EPS ($) -1.74 -1.84 -1.72 -1.03
EPS without NRI ($) -1.74 -1.84 -1.72 -1.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CBMG

Headlines

Articles On GuruFocus.com
Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility Sep 22 2017 
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial Sep 19 2017 
Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference Sep 14 2017 
Cellular Biomedicine Group (CBMG) Announces Stock Repurchase Program Jun 01 2017 
Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion May 15 2017 
Cellular Biomedicine Group Announces Results of 2017 Annual Meeting of Stockholders May 01 2017 
Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnersh Apr 10 2017 
Cellular Biomedicine Group (CBMG) Announces Completion of Wuxi GMP Facility Expansion Mar 30 2017 
Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders Mar 21 2017 
Small Cap Biotech Growth Stocks For 2015 Mar 05 2015 

More From Other Websites
Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility Sep 22 2017
One Thing To Consider Before Buying Cellular Biomedicine Group Inc (CBMG) Sep 20 2017
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial... Sep 19 2017
Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference Sep 14 2017
ETFs with exposure to Cellular Biomedicine Group, Inc. : September 6, 2017 Sep 05 2017
Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24,... Aug 24 2017
Streetwise Reports Examines One Regenerative Medicine Firm to 'Keep a Close Eye On' Aug 18 2017
Cellular Biomedicine reports 2Q loss Aug 08 2017
Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business... Aug 08 2017
ETFs with exposure to Cellular Biomedicine Group, Inc. : July 11, 2017 Jul 11 2017
Cellular Biomedicine Group (CBMG) Appoints Dr. Xia Meng as Chief Operating Officer to Lead... Jun 26 2017
ETFs with exposure to Cellular Biomedicine Group, Inc. : June 5, 2017 Jun 05 2017
Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Jun 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}